<![CDATA[Hansa Biopharma - Investorpræsentation]]>Presentation from Thursday around Gene Therapy by our Global Franchise Lead Lena Winstedt (in Swedish):

Just a moment...

favicon

(www.redeye.se)

Hansa Biopharma har en betalt digital IR-aftale med Proinvestor.com

]]>https://dev.proinvestor.com/forum/topic/444998/hansa-biopharma-investorprsentationRSS for NodeThu, 25 Jun 2026 14:58:05 GMTSat, 22 Apr 2023 04:27:01 GMT60<![CDATA[Reply to Hansa Biopharma - Investorpræsentation on Mon, 24 Apr 2023 09:09:20 GMT]]>The Chicago-based investment bank "William Blair" (analyst Matt Phipps) has initiated coverage on Hansa Biopharma

Hansa Biopharma AB (HNSA) - Turning the TIdeS: Imlifidase Provides a Novel Solution to Widen Transplant Access and Treat Antibody-Driven Acute Disease.

Læs hele analysen:

112289_20230424_HNSA___William_Blair_Turning_the_TIdeS__initiation_.pdf

]]>https://dev.proinvestor.com/forum/post/9482477https://dev.proinvestor.com/forum/post/9482477Mon, 24 Apr 2023 09:09:20 GMT<![CDATA[Reply to Hansa Biopharma - Investorpræsentation on Mon, 24 Apr 2023 04:47:57 GMT]]>Hansa Biopharma - Presentation of Q1 interim report 2023

Hansa Biopharma published its Q1 report on April 20th.

On that occasion, HC Andersen Capital will be hosting a digital event on Monday, April 24th at 13.00

Link Preview Image
Inderes – Presentation of Q1 2023

Tid: 24.04.2023, 13.30 Sprog: en Inderes is expected to report its Q1 2023 financial results on 21 April. Inderes’ CEO Mikael Rautanen will present the Q1 results on 24 April at 13:30 (CEST) in a virtual live event followed by a Q&A session.

favicon

Inderes (www.inderes.dk)

]]>https://dev.proinvestor.com/forum/post/9482471https://dev.proinvestor.com/forum/post/9482471Mon, 24 Apr 2023 04:47:57 GMT<![CDATA[Reply to Hansa Biopharma - Investorpræsentation on Sat, 22 Apr 2023 06:14:48 GMT]]>Urban - I dit link står der: 1.34 %.

If. Finansinspektionen (Blankningsregistret): 4,61% (2023-04-21). Listan uppdaterades: 2023-04-22 00:43)).

]]>https://dev.proinvestor.com/forum/post/9482476https://dev.proinvestor.com/forum/post/9482476Sat, 22 Apr 2023 06:14:48 GMT<![CDATA[Reply to Hansa Biopharma - Investorpræsentation on Sat, 22 Apr 2023 05:46:03 GMT]]>Shorting: Active positions for Hansa Biopharma

Link Preview Image
shortnordic.com - updated short positions

Free daily updates of short positions and live market prices. See which stocks and companies are shorted and how much the players earn and lose on their positions.

favicon

(shortnordic.com)

]]>https://dev.proinvestor.com/forum/post/9482473https://dev.proinvestor.com/forum/post/9482473Sat, 22 Apr 2023 05:46:03 GMT<![CDATA[Reply to Hansa Biopharma - Investorpræsentation on Sat, 22 Apr 2023 04:38:04 GMT]]>Opdatering fra HCW:

112231_20230421_HNSA_HCW_Imlifidase_Market_Grows_in_Europe_and_HNSA_5487___s_Clinical_Development_Begins_.pdf

]]>https://dev.proinvestor.com/forum/post/9482469https://dev.proinvestor.com/forum/post/9482469Sat, 22 Apr 2023 04:38:04 GMT<![CDATA[Reply to Hansa Biopharma - Investorpræsentation on Sat, 22 Apr 2023 04:36:27 GMT]]>Opdatering fra Carnegie;

112230_20230421_HNSA___Carnegie_Sales_still_slow_but_increased_confidence_in_acceleration_in_H2_23_.pdf

]]>https://dev.proinvestor.com/forum/post/9482470https://dev.proinvestor.com/forum/post/9482470Sat, 22 Apr 2023 04:36:27 GMT<![CDATA[Reply to Hansa Biopharma - Investorpræsentation on Sat, 22 Apr 2023 04:35:31 GMT]]>Opdatering fra Erik Penser Bank:

112229_20230421_HNSA___EP_Hansa_Biopharma___Ljusning_i_horisonten.pdf

]]>https://dev.proinvestor.com/forum/post/9482474https://dev.proinvestor.com/forum/post/9482474Sat, 22 Apr 2023 04:35:31 GMT<![CDATA[Reply to Hansa Biopharma - Investorpræsentation on Sat, 22 Apr 2023 04:34:20 GMT]]>Opdatering fra ABG:

112228_20230421_HNSA_ABG_Improved_performance_later_in__23.pdf

]]>https://dev.proinvestor.com/forum/post/9482465https://dev.proinvestor.com/forum/post/9482465Sat, 22 Apr 2023 04:34:20 GMT<![CDATA[Reply to Hansa Biopharma - Investorpræsentation on Sat, 22 Apr 2023 04:33:04 GMT]]>Opdatering fra RedEye:

112227_20230421_HNSA_Redeye_Development_progress_combined_with_modest_sales.pdf

]]>https://dev.proinvestor.com/forum/post/9482463https://dev.proinvestor.com/forum/post/9482463Sat, 22 Apr 2023 04:33:04 GMT<![CDATA[Reply to Hansa Biopharma - Investorpræsentation on Sat, 22 Apr 2023 04:31:49 GMT]]>Opdateret analyse fra SEB.

112226_20230421_HNSA_SEB_Light_at_the_end_of_the_tunnel_just_came_in_view.pdf

]]>https://dev.proinvestor.com/forum/post/9482467https://dev.proinvestor.com/forum/post/9482467Sat, 22 Apr 2023 04:31:49 GMT